Nanobodies Market Report

To learn more about this report, Download Free Sample Report

Global Nanobodies Market Size

The global nanobodies market size was valued at USD 482.16 million in 2025 and is estimated to reach USD 3650.20 million by 2034 from USD 603.77 million in 2026, registering a CAGR of 25.22% from 2026 to 2034.

MARKET DRIVERS

The growing number of R&D activities and increasing efforts from the pharmaceutical companies for the development of treatments for diseases such as cancer and diabetes fuel the demand for nanobodies and drive the market growth. For instance, on Jan 21, 2023, article published in the National Library of Medicine stated that targeting nanobodies for PSA or PSMA is simple to manufacture. Nanobodies can be employed in the creation of biosensors for the more accurate detection of prostate cancer for diagnostic reasons, and they can also be used to create immunotoxic and ADC medicines for therapeutic purposes. Preclinical in-vivo and in-vitro tests have demonstrated the viability of this treatment strategy.

The growing number of approvals for nanobodies from regulatory authorities further contribute to the growth of the nanobodies market. The rising awareness about early diagnosis propel the growth of the nanobodies market. For instance, the Government Royapettah Hospital (GRH) in India sponsored a breast cancer awareness programme in October 2020. This programme aims to raise awareness about breast cancer and early identification to prevent the disease from progressing. They attach to the antigens on the surface of cancer cells utilising nanobodies, which act as replacements for naturally existing antibodies in the treatment of cancer. This aids in the detection of cancer cells and the prevention of their proliferation. This may assist in lowering the incidence of cancer. Similarly, October 13 is designated as Metastatic Breast Cancer Awareness Day across the country in the US.

The high specificity and affinity of nanobodies in targeting complex biomolecules, increasing applications of nanobodies in diagnostics and therapeutics for various diseases, reduced immunogenicity and enhanced stability of nanobodies and the efficient penetration of tissues and tumors due to small size supports the nanobodies market growth. The potential for multi-specific binding and modular design, rapid development and production using recombinant technology, rising interest in personalized medicine and precision therapeutics, growing demand for targeted cancer therapies with minimal side effects and advancements in phage display and antibody engineering techniques fuel the growth rate of the nanobodies market. Opportunity for oral delivery and crossing biological barriers, potential use as molecular imaging agents for in-vivo studies, the development of nanobody-based drug conjugates and fusion proteins and the emergence of biotech startups specializing in nanobody research propel the market growth.

MARKET RESTRAINTS

High costs associated with the production and limitations for production majorly inhibits the market growth. For instance, in November 2021, a research centre in the United States created small proteins called nanobodies. These nanobodies were priced at $9,000. However, producing nanobodies can be more hazardous compared to other types of antibodies called monoclonal and polyclonal antibodies. This is because there are certain potentially dangerous substances involved in the production of nanobodies, such as harmful bacteriophages. This means that developing nanobodies requires more complex methods of taking care of these animals to get the desired antibodies.

Limited clinical validation and regulatory approval for certain applications, challenges in large-scale production and purification of nanobodies, competition from established antibody therapies and other biologics and a complex intellectual property landscape affecting research and development further hinder the market growth. High research and development costs for new nanobody candidates, limited availability of standardized protocols for nanobody generation, variability in nanobody pharmacokinetics and tissue distribution and challenges in developing efficient delivery systems for therapeutic use hamper the nanobodies market growth.

REPORT COVERAGE

SEGMENTAL ANALYSIS

By Product Type Insights

Based on product type, the monospecific nanobodies segment is anticipated to account for the largest share of the global market in the coming years. The simplicity and ability of monospecific nanobodies to target single antigens with high specificity, making them valuable tools in diagnostics and research applications and is one of the major factors driving the segmental growth. The growing demand for molecular probes for research, diagnostics, and imaging and versatile applications of monospecific nanobodies in drug discovery, disease biomarker identification and therapeutic development further fuel the growth rate of the monospecific nanobodies segment in the global market.

The multi-specific nanobodies segment is anticipated to hold a considerable share of the global market in the coming years. The growing interest in combination therapies targeting multiple pathways or antigens, the potential for improved therapeutic outcomes by targeting complex diseases, and the expansion of immuno-oncology and personalized medicine applications drive the growth of the multi-specific nanobodies segment in the global market.

By Application Insights

Based on application, the research segment is expected to account for the leading share of the global market during the forecast period owing to the high demand for molecular tools to elucidate complex biological mechanisms. Rapid and specific targeting of proteins for functional studies and drug discovery and increasing number of research activities in immunology, structural biology, and cell signaling further fuel the growth rate of the research segment in the global market.

The therapeutics segment is expected to register a healthy CAGR during the forecast period. The growing interest in antibody-based therapies with enhanced specificity, the ability of nanobodies to reach challenging targets and penetrate tissues and the potential for reduced immunogenicity and novel treatment modalities boost the growth of the therapeutics segment in the global market.

By Distribution Channel Insights

Based on the distribution channel, the hospital pharmacies segment is expected to capture a substantial share of the global market during the forecast period. Factors such as high demand for innovative therapies in hospital settings, direct collaboration with healthcare professionals for personalized treatments and rapid delivery of critical therapies to patients undergoing treatment majorly propel the growth of the hospital pharmacies segment in the global market.

REGIONAL ANALYSIS

North America led the market in 2025 and dominates the market during the forecast period. For instance, Alphamab Oncology, a developer and producer of novel therapeutic drugs for the treatment of cancer, announced on April 29, 2021, that it had entered into a clinical trial collaboration and supply agreement with Pfizer Inc., to assess the efficacy and safety of KN046, a recombinant humanised bispecific antibody, when combined with Inlyta (axitinib) for the first-line treatment of non-small cell lung cancer (NSCLC). Strong presence of leading biotechnology and pharmaceutical companies, high prevalence of chronic diseases and cancer, growing number of academic and research collaborations, favorable regulatory environment supporting biologics and targeted therapies and the presence of well-developed healthcare systems that promote early adoption of novel treatments further contribute to the growth of the North American market.

Europe is a prominent regional market for nanobodies and is anticipated to account for a noteworthy share of the global market during the forecast period. The presence of advanced research institutions and increasing number of academic collaborations enhancing nanobody discoveries drive the growth of the European nanobodies market growth. Belgium and the Netherlands are pioneers in nanobody research in the European region. Factors such as supportive regulatory framework for biologics and innovative therapies, rising adoption of precision medicine and targeted treatments, rising focus on rare diseases and orphan drug development and the presence of well-established clinical trial networks accelerating the evaluation of nanobody therapeutics fuel the growth rate of the European market.

The APAC is predicted to be the most lucrative regional market for nanobodies and is anticipated to capture a considerable share of the worldwide market during the forecast period. The growing clinical trial activity for nanobody-based therapeutics, rapid adoption of precision medicine approaches and growing prevalence of cancer and chronic diseases fuels interest in advanced therapies and propel the APAC market growth. China followed by India and South Korea are expected to hold the leading share of the APAC market during the forecast period.

KEY MARKET PLAYERS

Some of the major companies in the global nanobodies market.

• Merck KGaA
• Sanofi (Ablynx)
• Alphamab Oncology
• Novartis AG
• Genscript
• Taisho Pharmaceutical Holdings Co., Ltd.
• Sensei Biotherapeutics, Inc.
• Cusabio Technology LLC
• ChromoTek GmbH
• Beroni Group
• ExeVir Bio BV
• Absolute Antibody
• Alpalife (Shenzhen Kangti Co., Ltd.)
• DiosCURE Therapeutics SE
• Thermo Fisher Scientific Inc.
• PerkinElmer Inc. (BioLegend, Inc.)
• Abnova Corporation

RECENT MARKET HAPPENINGS

• In July 2021, DiosCURE Therapeutics SE, a manufacturer of immuno therapeutics signed an exclusive licensing agreement with research and invention parties such as University Hospital Bonn, Macrostruct Holding & Consulting AB and Scripps Research a broad suite of intellectual property including DIOS203, DIOS202, and DIOS301 highly effective therapy against SARS-CoV-2.
• In March 2021, Taisho Pharmaceutical Co., Ltd., a pharmaceutical manufacturer of analgesics, applied of approval for manufacturing and marketing the anti-TNFα NANOBODY therapeutic licensed from Ablynx, a subsidiary of Sanofi S.A. in 2015, developed by Taisho Pharmaceutical Co., Ltd., in Japan, submitted to the Ministry of Health, Labour and Welfare of Japan for the indication of rheumatoid arthritis (RA).
• In June 2019, the FDA approved the first nanobody, lifting hopes for companies that are exploring innovative uses for domain antibodies.

MARKET SEGMENTATION

This research report on global nanobodies market has been segmented and sub-segmented based on the following categories.

By Product Type

• Monospecific Nanobodies
• Monovalent Nanobodies
• Multivalent Nanobodies
• Bi-para topic Nanobodies
• Multispecific Nanobodies
• Fusion Nanobodies

By Application

• Research
• Therapeutics
• Diagnostics

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• The Middle East & Africa